Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Understand the reasons for choosing a retirement plan over a 401k. Make informed decisions for a secure retirement.
23,531 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Stocks wiggle as CoreWeave drops on news of Blue Owl’s failed $4B debt placement. Experts say the financing hiccup co...
Fannie Freddie Boldly Remove the 620 FICO floor marks a historic change in conventional lending. This article explain...
Netflix faces a crossroads: expand by merging with major studios or double down on core strengths. This piece argues ...
Ukraine expands its drone-defense footprint in the Middle East, signaling a broader role for Kyiv as global markets w...
Intel has surged 116% in the past month as AI demand strengthens data-center demand and early talks of a potential Ap...
When a leading fund sells a sizable stake in a cyclical manufacturer after a rough quarter, investors want clarity. T...
A notable fund just built a fresh position in a cloud security leader. Discover the numbers behind winmill loads qual...
The Federal Housing Administration announces the resignation of Commissioner Frank Cassidy, effective June 1, ending ...
When wholesale prices rise, most consumer staples stocks feel the pinch. Coca-Cola, however, has shown resilience. Th...
Investors often chase compelling stories more than spreadsheets. This piece explores historical price dynamics and ho...
June brought a momentum burst in niche tech, led by space-based connectivity. This article breaks down the stock mark...